Etherlipid-containing multiple lipid liposomes

Details Etherlipid-containing multiple lipid liposomes Etherlipid-containing multiple lipid liposomes

2006-03-28

2006-03-28

Kishore, Gollamudi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C428S402200

Reissue Patent

active

RE039042

ABSTRACT:
Described herein are liposomes containing etherlipids of the formula:as well as a phosphatidylcholine, a sterol, and a headgroup-derivatized lipid. These liposomes are useful in a variety of therapeutic regimens, including the treatment of cancers and inflammatory disorders.

REFERENCES:
patent: 3752886 (1973-08-01), Munder et al.
patent: 4159988 (1979-07-01), Eibl et al.
patent: 4163748 (1979-08-01), Eibl et al.
patent: 4382035 (1983-05-01), Eibl
patent: 4734225 (1988-03-01), Eibl
patent: 4804789 (1989-02-01), Eibl
patent: 4920016 (1990-04-01), Allen et al.
patent: 4965391 (1990-10-01), Counsell et al.
patent: 4983397 (1991-01-01), Schroit et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5436234 (1995-07-01), Eibl
patent: 5762958 (1998-06-01), Mayhew
patent: 4132345 (1993-04-01), None
patent: 4408011 (1995-11-01), None
patent: 1583661 (1981-01-01), None
patent: 072294 (1984-07-01), None
patent: 93/04673 (1993-03-01), None
patent: 93/08202 (1993-04-01), None
patent: 94/27580 (1994-12-01), None
Bazill, et al., “Role of Endocytosis in the Action of Ether Lipids on WEHI-3B, HL60, and FEDCP-Mix A4 Cells”, Cancer Res. 50: 7505 (1990).
Berdel, “Membrance-interactive lipids as experimental anti-cancer drugs”, Br. J. Cancer 64: 208 (1991).
Berdel, “Ether Lipids and Derivatives as Investigational Anticancer Drugs”, Onkologie, 1990, 13: 245, Karger Publishers, Freiburg, Germany.
Bhatia et al., “Sterospecific Systhesis of Antitumor Active Thioether PAF Analogs”, Lipids, 1991, 26(12): 1424, Baylor College of Medicine, Houston, Texas.
Blume et al., “Specific Targeting with Poly(ethylene Glycol)-Modified Liposomes: Coupling of Homing Devices to the Ends of the Polymeric Chains Combines Effective Target Binding with Long Circulation Times”, Biochim. Biophys. Acta., 1993, 1149: 180-184, Elsevier, Amsterdam, The Netherlands.
Daicho et al., “Effects of Alkyl Glycosides Incorporated into Liposomes Prepared from Synthetic Amphiphiles on Their Tissue Distribution in Ehrlich Solid Tumor-Bearing Mice”, BBA, 1992, 1107: 61, Elsevier, Amsterdam, The Netherlands.
Darnell et al., “Molecular Cell Biology”, 1986, pp. 573-575, Scientific American Books, Inc., New York New York.
Deamer et al., “Liposome Preparation: Methods an Mechanisms” in Liposomes (M. Ostro, editor), 1983, pp. 27-52, Marcel Dekker, Inc., New York, New York.
Dietzfelbinger et al., “Removal of Breast Cancer Cells from Bone Marrow by In Vitro Purging with Ether Lipids an Cryopreservation”, Cancer Res., 1993, 53: 3747, American Association for Cancer Research, Baltimore, Maryland.
Dive et al., “Multiparametric Flow Cytometry of the Modulation of Tumor Cell Membrane Permeability by Developmental Antitumor Ether Lipid SRI 62-834 in EMT6 Mouse Mammary Tumor and HL-60 Human Promycyocytic Leukemia Cells”, Cancer Res., 1991, 51: 799, American Association for Cancer Research, Baltimore, Maryland.
Gabizon et al., “Prolongation of Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs”, Pharm. Res., 1993, 10(5): 703, Elsevier, Amsterdam, The Netherlands.
Kaufmann-Kolle et al., “Liposomal Hexadecylphosphocholine (HEPC): In Vitro and In Vivo Application”, Chemical Abs. 4: 10.08, Stanford University Libraries, Stanford, Calfornia.
Layton et al., “The Interaction of Liposomes with Cells: The Relation of Cell Specific Toxicity to Lipid Composition”, Eur. J. Cancer, 1980, 16: 64, Elsevier, Amsterdam, The Netherlands.
Lewis et al., “The Mesomorphic Phase Behavior of Lipid Bilayers”, in The Structure of Biological Membranes (P. Yeagle, editor), 1992, pp. 73-155 at pp. 123-126, CRC Press, Inc., Boca Raton, Florida.
Muschiol et al., “Alkyl Phosphocholine: Toxicity and Anti-cancer Properties”, Lipids, 1987, 22(11): 930, Baylor College of Medicine, Houston, Texas.
Nairn, in Remington's Pharmaceutical Science (A. Gennaro, editor), 1985, pp. 1492-1517, Mack Publishing Co., Easton, Pennsylvania.
Park et al., “Some Negatively Charged Phospholipid Derivatives Prolong the Liposome Circulation In Vivo”, Biochim. Biophys. Acta., 1992, 1108: 257, Elsevier, Amsterdam, The Netherlands.
Powis et al., “Selective Inhibition of Phosphatidylinositol Phospholipase C by Cytoxic Ether Lipid Analogues”, Cancer Res., 1992, 52: 2835, American Association for Cancer Research, Baltimore, Maryland.
Powis et al., “The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy”, Cancer Res., 1990, 50: 2203, American Association for Cancer Research, Baltimore, Maryland.
Reed et al., “Antioneoplastic Ether-Linked Phospholipid Induces Differentiation of Acute Myelogenous Leukemic KG-1 Cells into Marcophase-Like Cells”, Life Sci., 1991, 49: 1221, Pergamon Press, Oxford, England.
Runge et al., “Destruction of Human Solid Tumors by Alkyl Lysophopholipids”, JNCI, 1980, 64(6): 1301, Oxford University Press, Oxford, England.
Tritton et al., “How to Kill Cancer Cells: Membranes and Cell Signaling as Targets in Cancer Chemotherapy”, Cancer Cells, 1990, 2(4): 95, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Workman, “Antitumor Ether Lipids: Endocytosis as a Determinant of Cellular Sensitivity”, Cancer Cells, 1991, 3(8): 315, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Workman et al., “Plastelet-activating Factor (PAF) Antagonist WEB 2086 Does not Modulate the Cytotoxicity of PAF or Antitumor Alkyl Lysophospholipids ET-18-O-Methyl and SRIU 62-834 in HL-60 Promyelocytic Leukemia Cells”, Biochem. Pharmacol., 1991, 41(2): 319, Elsevier, Amsterdam, The Netherlands.
Zeisig et al., “Antioneoplastic Activity In Vitro of Free and Liposomal Alkylphophocholines”, Anti-Cancer Drugs, 1993, 4: 57, Lippincott Williams & Wilkins, Amsterdam, The Netherlands.
Kuchera et al., “Novel Membrane-Interactive Ether Lipid Analogs that Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation”, AIDS Res. & Human Retroviruses, 1990, 6(4): 491-501, Mary Ann Liebert, Inc., Publishers, New York, New York.
Baker et al., “Inhibition of Chronic Relapsing Experimental Allergic Encephalomyelitis in the Mouse by the Alkyl-Lysophospholipid ET-18-OCH3”, Int. J. Immunopharm, 1991, 13(4): 385-392, International Society for Immunopharmacology, Pergamon Press pic, Oxford, England.
Mende, Chem Abstracts, 119(23): 205219 g, Stanford University Libraries, Stanford, Calfornia.
Zalipsky et al., “Long Circulating, Cationic Liposomes Containing Amino-PEG-Phosphatidylethanolamine”, FEBS Letters, 1994, 353: 71-74, Federation of European Biochemical Societies, Elsevier Science BV, Amsterdam, The Netherlands.

Affiliated with

Also associated with

Rating

Etherlipid-containing multiple lipid liposomes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Etherlipid-containing multiple lipid liposomes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Etherlipid-containing multiple lipid liposomes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3589340